Received by email:

File: MedX Names Louie Canitano press release _final_3.pdf

                                                                                  Press Release

For Immediate Release

                                       MEDX HEALTH CORP.
                                               NEWS RELEASE

TSX Venture Symbol: MDX                                                    CUSIP #: 585090

        MedX Names Louie Canitano as President and Chief Operating Officer


April 5th, 2013 - Ontario, Canada:, MedX Health Corp. ("MDX" or the "Company", TSX � MDX) announced
today that the Board of Directors has appointed Louie Canitano as President and Chief Operating Officer
effective immediately.

In his new role as President and Chief Operating Officer Mr. Canitano will oversee all operational, financial,
and corporate aspects of the Company and will focus on executing the strategic plan approved by the Board.
MedX's patented medical device technology for the early detection of skin cancer is the Company's leading
product and as such will be the focal point of its development and marketing strategy. This product has the
potential to create a new and substantial revenue stream for MedX.

Mr. Canitano joined MedX in February 2010 as Executive Vice President, Operations. He has a deep
understanding of operating emerging growth medical device technology companies, and brings to MedX over
18 years of operational medical device experience focusing on engineering, proprietary intellectual property,
management and corporate assignments. Mr. Canitano is uniquely suited to anticipate trends and quickly
respond to regulatory changes and financing challenges, and has experience in all sectors including Sales and
Marketing, Regulatory, IP, Design and Development, and also holds a patent surrounding laser therapy. Mr.
Canitano began his career with managing "G" Code and Schedule 5 based OHIP physiotherapy and multi-
disciplinary clinics, introducing and utilizing laser therapy as a palliative modality. He has a Bachelor of
Sciences in Natural Health Sciences.

Mr. Canitano states, "Skin cancer represents the fastest growing form of cancer in the World and affects all age
groups. Detecting skin cancer early is the key to long-term survival rates and therefore MedX will seek unique
strategic relationships that give ease of access to our technology. This includes partnering with thought leaders,
advocacy partners, and strategic channel partners to ensure our technology has Global reach."

MedX is a global leader in the development, manufacture and distribution of leading edge quality patented
optical biopsy technology used in early diagnosis of skin cancer and low level laser light technology for use in
numerous medical settings for tissue repair including rehab/sports medicine, dentistry, wound care, and pain
management.

This news release may contain assumptions, estimates, and other forward-looking statements regarding future
events. Such forward-looking statements involve inherent risks and uncertainties and are subject to factors,
many of which are beyond the Company's control that may cause actual results or performance to differ
materially from those currently anticipated in such statements.




                                                      Page 1
                                                                                                   Press Release

For further information, please contact Steve Guillen, Chief Executive Officer at (905) 670-4428 Email
inquiries should be made to: Steve.Guillen@medxhealth.com and the company website is located at
www.medxhealth.com. Inquiries by direct mail should be addressed to; MedX Health Corp. 220 Superior
Blvd., Mississauga, Ontario, L5T 2L2

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information set out in this News Release constitutes forward-looking information. Forward-looking statements (
--->often, but not
always, identified by the use of words such as "expect", "may", "could", "anticipate" or "will" and similar expression
--->s) may describe
expectations, opinions or guidance that are not statements of fact and which may be based upon information provided by
---> third parties.
Forward-looking statements are based upon the opinions, expectations and estimates of management of MDX as at the date
---> the
statements are made and are subject to a variety of known and unknown risks and uncertainties and other factors that c
--->ould cause
actual events or outcomes to differ materially from those anticipated or implied by such forward-looking statements. A
--->lthough MDX
believes that the expectations reflected in the forward-looking statements set out in this press release or incorporat
--->ed herein by
reference are reasonable, it can give no assurance that such expectations will prove to have been correct. The forward
--->-looking
statements of MDX contained in this News Release, or incorporated herein by reference, are expressly qualified, in the
--->ir entirety, by this
cautionary statement and the risk factors contained in MDX's current annual information form available at www.sedar.co
--->m.




                                                                Page 2